• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Abbott expands Lingo OTC CGM to Android devices

December 8, 2025 By Sean Whooley

Abbott Lingo over-the-counter CGM available for Android
[Image courtesy of Abbott]
Abbott (NYSE:ABT) announced today that it made its Lingo over-the-counter continuous glucose monitor (CGM) and app available for Android devices.

The company already offered the Lingo biowearable for Apple iOS devices. Expanding to Android could bring Lingo to millions more people looking to access real-time glucose data. The Lingo app is now available for download for Android through the Google Play Store and continues to be available for iOS on the Apple App Store.

Lingo features a biosensor and mobile app designed for customers who want to improve their overall health and wellness. The company built Lingo on its FreeStyle Libre CGM technology platform. The consumer biowearable is available for consumers 18 years and older not on insulin. It tracks glucose in real time and provides personal insights and coaching. The company designed it to help people build healthy habits, retain their metabolism and improve their overall well-being.

Abbott received FDA clearance for Lingo and its Libre Rio OTC CGMs in June 2024. Lingo is one of two OTC CGMs on the market, with Dexcom’s Stelo also an option for those seeking to monitor glucose levels. Abbott EVP of Diabetes Care, Chris Scoggins, explained the benefits of OTC CGMs and other offerings earlier this year.

Read more about Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Visit here to purchase our Medtech Market Special Report on CGMs.

This marks the latest expansion for Lingo as it penetrates different markets, starting with a launch through Amazon as its first retail agreement for the device earlier this year, then with Walmart as the first brick-and-mortar retailer for the CGM.

Abbott says Lingo makes glucose insights more accessible and actionable. It utilizes Lingo Count, a daily metric that shows how much glucose spikes affect the body.

“Glucose levels and metabolic health are foundational for overall well-being and chronic disease prevention. The need for more glucose awareness is clear,” said Amy McKenzie, head of Medical Affairs for Abbott’s Lingo business. “Prediabetes – a condition where glucose is elevated but not yet in the diabetes range – impacts more than 98 million U.S. adults, yet 80% of those affected don’t know they have it. With awareness and lifestyle changes, prediabetes can be managed or reversed. Lingo provides the insight needed to help people understand their glucose patterns in real time, empowering informed choices that support better metabolic health.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott

IN CASE YOU MISSED IT

  • MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
  • Abbott wins FDA authorization for dual glucose-ketone sensor
  • FDA clears Roche’s Alzheimer’s blood test for rule-in and rule-out assessment 
  • MiniMed Flex now integrated with Abbot’s Instinct sensor 
  • Senseonics sees activist investor take a major stake

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS